Abstract:Piperine (PIP), the major alkaloid component from Piper longum L. and Piper nigrum L., could enhance the bioavailabilities of other drugs including rosuvastatin, peurarin and docetaxel (DOX) via inhibition of CYP3A and P-glycoprotein activity. Nevertheless, the effect of such drug combination usage on the in vivo exposure of PIP has not been investigated due to lack of assay for the simultaneous determination of PIP and other drugs such as DOX. Besides, the reported pharmacokinetics of PIP varied a lot without appropriate bioavailability determined from the same dose. In the current study, an LC/MS/MS method has been developed to simultaneously determine the plasma concentrations of PIP and DOX and further applied to investigate the pharmacokinetics properties of PIP after oral and intravenous administrations as well as the pharmacokinetics interactions between PIP and DOX after their co-administration. A simple protein precipitation method was employed for plasma sample treatment by adding a mixture of methanol and acetonitrile (1:1, v/v) with glibenclamide as internal standard (IS). The LC/MS/MS system consisted of Agilent 6430 series LC pumps and auto-sampler. The chromatographic separation was carried out in 15min on a Waters C18 column (150×3.9mm i.d., 4μm) with a mobile phase containing 0.2% formic acid and acetonitrile (1:1, v/v) at a flow rate of 0.4ml/min. The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS. The method demonstrated good linearity for both PIP and DOX over the concentration range of 2.5-1280ng/ml with LLOD at 2.5ng/ml. The intra-day and inter-day precisions were less than 13.34% and relative error (R.E.) representing accuracy was in the range of -11.38 to 3.15%. The recoveries of PIP, DOX and IS were above 75% and there was no matrix effect. PIP and DOX exhibited good stabilities under various conditions. PIP was administrated via intravenous bolus at 3.5mg/kg and via oral administration at 35mg/kg and 3.5mg/kg, while DOX was intravenously administrated at 7mg/kg to Sprague-Daley rats. The plasma concentrations of PIP and DOX were determined using the above developed and validated method. At the dose of 3.5mg/kg, the bioavailability of PIP was calculated to be 25.36%. Its AUC0→t was unproportionally increased with doses, indicating a potential non-linear pharmacokinetics profile of PIP. It was found that the AUC0→t and C0 of DOX and t1/2 of PIP were significantly increased after their combination use, suggesting potential enhanced bioavailability of not only DOX but also PIP, which may lead to the overall enhanced pharmacological effects.

Bioavailability enhancement of formononetin by incorporation of natural bioenhancer in phospholipid complex

Enhanced Bioavailability of the Poorly Water-Soluble Drug Fenofibrate by Using Liposomes Containing a Bile Salt

Preparation, Characterization and in Vivo Evaluation of Bergenin-Phospholipid Complex

A phospholipid complex to improve the oral bioavailability of flavonoids

Non-linear Pharmacokinetics of Piperine and Its Herb-Drug Interactions with Docetaxel in Sprague-Dawley Rats.

Formulation and Development of Novel Matrix Dispersion System based on Phospholipid Complex for Improving Oral Bioavailability of Ferulic Acid

Enhanced Oral Bioavailability of Isoformononetin Through Nanoemulsion: Development, Optimization, and Characterization

In vitro evaluation and in situ intestinal absorption characterisation of paeoniflorin nanoparticles in a rat model

Piperine Fast Disintegrating Tablets Comprising Sustained-Release Matrix Pellets with Enhanced Bioavailability: Formulation, in Vitro and in Vivo Evaluation

Fenofibrate Solid Dispersion Processed by Hot-melt Extrusion: Elevated Bioavailability and Its Cell Transport Mechanism.

Using the Cocrystal Approach as a Promising Drug Delivery System to Enhance the Dissolution and Bioavailability of Formononetin Using an Imidazole Coformer

The Use of Lipid-Based Formulations to Increase the Oral Bioavailability of Panax Notoginseng Saponins Following a Single Oral Gavage to Rats

Development and characterisation of ibuprofen-loaded nanoemulsion with enhanced oral bioavailability

Enhancing the Solubility of Fenofibrate by Nanocrystal Formation and Encapsulation

Formononetin-Loaded Self-Microemulsion Drug Delivery Systems for Improved Solubility and Oral Bioavailability: Fabrication, Characterization, In Vitro and In Vivo Evaluation

Formulation Optimization of Fenofibrate Nanomatrix System by Response Surface Methodology based on Central Composite Design and In Vivo Bioavailability Evaluation

Enhanced solubility and biological activities of Flufenamic acid through β-Cyclodextrin derivatives inclusion complexes: A comprehensive study

Folic acid-conjugated long circulating co-encapsulated atorvastatin and quercetin solid lipid nanoparticles: pharmacokinetics and biodistribution in rats

Enhancing ketoprofen's solubility and anti-inflammatory efficacy with safe methyl-β-cyclodextrin complexation

Enhanced Solubility and Bioavailability of Naringenin Via Liposomal Nanoformulation: Preparation and in Vitro and in Vivo Evaluations